Friday, 16 October 2026European Markets

LECTRA Stock Bearish By 10% So Far On Monday

Loading stream...

(vianews) - shares of lectra (cac 40: lss.pa) fell by a staggering 10.61% to €29.50 at 14:56 est on monday, after five consecutive sessions in a row of losses. cac 40 is rising 0.1% to €7,491.50, after two sequential sessions in a row of gains. this seems, up to now, a somewhat positive trend exchanging session today.

about lectra

lectra sa designs smart industrial solutions for fashion, automotive, and furniture markets. the company's solutions include software, automated cutting equipment, and related services, which enable customers to automate and optimize product design, development, and manufacture of garments, car seats and interiors, airbags, and sofas, as well as to digitalize their processes. it also offers technical maintenance, support, training, and consulting services; and sells consumables and parts. the company operates in europe, the americas, the asia-pacific, and internationally. lectra sa was founded in 1973 and is headquartered in paris, france.

earnings per share

as for profitability, lectra has a trailing twelve months eps of €1.

pe ratio

lectra has a trailing twelve months price to earnings ratio of 29.5. meaning, the purchaser of the share is investing €29.5 for every euro of annual earnings.

more news about lectra (lss.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com